Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Siga Bid for Reargument in PharmAthene Case Denied by Judge

Dec. 16 (Bloomberg) -- Siga Technologies Inc. failed to persuade a Delaware Chancery Court judge to reconsider his award of 50 percent of the profit from a smallpox drug to PharmAthene Inc., according to court papers.

In an opinion today, Judge Donald Parsons affirmed his earlier decision that Siga should share possible proceeds of more than $400 million.

“The standard applicable to a motion for reargument is well-settled,” and “ the moving party bears a heavy burden,” Parsons wrote in a 19-page opinion. “Motions for reargument must be denied when a party merely restates its prior arguments.”

New York-based Siga alleged in a court filing that Parsons “misapprehended both the law and the facts” in awarding a share of ST-246’s profit to Annapolis-based PharmAthene. Parsons earlier said Siga breached its obligation to negotiate in good faith on the antiviral drug designed for use in case of a biological attack.

The case is PharmAthene Inc. v. Siga Technologies Inc., CA2627, Delaware Chancery Court (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.